A Randomized Parallel Group Controlled Study between 3.75 mg of Leuprorelin and 1.8 mg of Goserelin Depot in the Sequential Therapy (GnRH Agonist + Dienogest) for Treatment of Endometriosis
Phase 4
Recruiting
- Conditions
- endometriosis, chocolate cyst or adenomyosis uteri
- Registration Number
- JPRN-UMIN000010332
- Lead Sponsor
- Tokyo Women's Medical University Department of Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with undiagnosed abnormal genital bleeding 2. Pregnant or possibly pregnant women 3. Lactating patients 4. Patients with a past history of hypersensitivity to GnRH agonists or dienogest 5. Patients treated with hormone drugs (oral contraceptive, danazol, GnRH agonists, etc.) and dienogest within the past 4 months 6. Other patients considered ineligible as subjects by investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method